Related Experiment Videos
Drug therapy after very-low-calorie diets
N Finer1, S Finer, R P Naoumova
1Department of Medicine, United Medical School, Guy's Hospital, London, England.
The American Journal of Clinical Nutrition
|July 1, 1992
Summary
Very-low-calorie diets (VLCDs) effectively reduce weight, but maintaining loss is challenging. Dexfenfluramine (dF) combined with VLCDs shows promise for sustained weight management in obese patients.
Area of Science:
- Obesity pharmacotherapy
- Metabolic disease management
- Weight management strategies
Background:
- Very-low-calorie diets (VLCDs) achieve significant weight reduction but long-term maintenance is difficult.
- Conventional weight regain prevention methods have limited applicability and success rates.
- Pharmacological interventions are needed to sustain VLCD-induced weight loss.
Purpose of the Study:
- To evaluate the efficacy of dexfenfluramine (dF) in maintaining weight loss after a VLCD.
- To assess the safety and effectiveness of pharmacological support for obesity treatment.
Main Methods:
- A double-blind trial randomized 45 patients post-VLCD to placebo or dexfenfluramine (dF) 15 mg twice daily for 26 weeks.
- Participants maintained a reduced-calorie diet (60-75% of daily energy needs).
Main Results:
- Dexfenfluramine (dF) combined with a VLCD demonstrated effectiveness in maintaining weight loss.
- The study assessed the role of serotonin agonists in obesity management.
Conclusions:
- Pharmacological treatment, such as with dexfenfluramine (dF), can be a valuable clinical tool for sustaining weight loss initiated by very-low-calorie diets (VLCDs).
- Further research into safe and effective obesity drugs is crucial for long-term metabolic health.